Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
|Videos|June 17, 2016
Considering Neoadjuvant Chemotherapy Options in Bladder Cancer
In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.
Advertisement
In this peer-to-peer discussion, Petros Grivas, MD, PhD, of the Cleveland Clinic in Cleveland, Ohio, and Phillip L. Palmbos, MD, PhD, of the University of Michigan in Ann Arbor, Michigan, examine the role of neoadjuvant chemotherapy in bladder cancer, weighing the various trial data that guide these treatment decisions, with considerations for patient comorbidities.
Financial Disclosure:Dr. Grivas is a consultant for Genentech.
Advertisement
Related to this article
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.
The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.
Melody Rasouli, MD, MBA, FACOG, discussed the system breakdowns that delay fertility referrals and how EHR triggers can automate the process.
Zachary L. Bercu, MD, RPVI, FSIR, discusses the Liberty robotic system’s applications in liver and kidney cancer as well as the feasibility of remote procedures.
Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy
2
Taking The First Steps for a Personalized Lung Cancer Vaccine Trial
3
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
4
Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC
5